Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.